Read More Pharma Industry News Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of… bypharmanewsdailyJanuary 20, 2019